A selanylimidazopyridine (3-SePh-IP) reverses the prodepressant- and anxiogenic-like effects of a high-fat/high-fructose diet in mice. (2nd March 2021)
- Record Type:
- Journal Article
- Title:
- A selanylimidazopyridine (3-SePh-IP) reverses the prodepressant- and anxiogenic-like effects of a high-fat/high-fructose diet in mice. (2nd March 2021)
- Main Title:
- A selanylimidazopyridine (3-SePh-IP) reverses the prodepressant- and anxiogenic-like effects of a high-fat/high-fructose diet in mice
- Authors:
- Veloso, Izolene Corrêa
Delanogare, Eslen
Machado, Adriano Emanuel
Braga, Sara Pereira
Rosa, Giovana Karoline
De Bem, Andreza Fabro
Rafique, Jamal
Saba, Sumbal
da Trindade, Roberth Nascimento
Galetto, Fábio Zazyki
Moreira, Eduardo Luiz Gasnhar - Abstract:
- Abstract: Objective: While chronic feeding with high-fat or high-sugar diets is known related to obesity and type 2 diabetes, later data have indicated that it is also related to depression and anxiety appearance. In this regard, multi-target drugs raise considerable interest as promising therapeutic solutions to complex diseases. Considering the pharmacological effects of the imidazopyridine-derivative moiety imidazo[1, 2- a ]pyridine and the organoselenium molecules, the combination of both could be a feasible strategy to develop efficient drugs to handle obesity and related comorbidities, for example dyslipidemia and mood disorders. Methods: The antidepressant- and anxiolytic-like properties of a selanylimidazopyridine compound, 2-Phenyl-3-(phenylselanyl)imidazo[1, 2- a ]pyridine (3-SePh-IP), were evaluated on high-fat/high-fructose diet (HFFD)-fed female Swiss mice. Key findings: Our results showed that a short-term HFFD (16 days) could promote a significant body weight gain, hypercholesterolemia, glucose intolerance, and anxiety- and depressive-like behaviour in mice. Concomitant treatment with 3-SePh-IP (10 mg/kg; i.p.) attenuated the HFFD-induced increase in cholesterol levels and blunted the anxiety- and depressive-like behaviour in mice. Conclusions: 3-SePh-IP holds multimodal pharmacological properties, which provide a rationale for further studies, for example to assess the underlying mechanisms linked to its anxiolytic- and antidepressive-like activities.Abstract: Objective: While chronic feeding with high-fat or high-sugar diets is known related to obesity and type 2 diabetes, later data have indicated that it is also related to depression and anxiety appearance. In this regard, multi-target drugs raise considerable interest as promising therapeutic solutions to complex diseases. Considering the pharmacological effects of the imidazopyridine-derivative moiety imidazo[1, 2- a ]pyridine and the organoselenium molecules, the combination of both could be a feasible strategy to develop efficient drugs to handle obesity and related comorbidities, for example dyslipidemia and mood disorders. Methods: The antidepressant- and anxiolytic-like properties of a selanylimidazopyridine compound, 2-Phenyl-3-(phenylselanyl)imidazo[1, 2- a ]pyridine (3-SePh-IP), were evaluated on high-fat/high-fructose diet (HFFD)-fed female Swiss mice. Key findings: Our results showed that a short-term HFFD (16 days) could promote a significant body weight gain, hypercholesterolemia, glucose intolerance, and anxiety- and depressive-like behaviour in mice. Concomitant treatment with 3-SePh-IP (10 mg/kg; i.p.) attenuated the HFFD-induced increase in cholesterol levels and blunted the anxiety- and depressive-like behaviour in mice. Conclusions: 3-SePh-IP holds multimodal pharmacological properties, which provide a rationale for further studies, for example to assess the underlying mechanisms linked to its anxiolytic- and antidepressive-like activities. Graphical Abstract: … (more)
- Is Part Of:
- Journal of pharmacy and pharmacology. Volume 73:Number 5(2021)
- Journal:
- Journal of pharmacy and pharmacology
- Issue:
- Volume 73:Number 5(2021)
- Issue Display:
- Volume 73, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 73
- Issue:
- 5
- Issue Sort Value:
- 2021-0073-0005-0000
- Page Start:
- 673
- Page End:
- 681
- Publication Date:
- 2021-03-02
- Subjects:
- imidazopyridine -- selenium -- behavioural -- obesity
Pharmacy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- https://academic.oup.com/jpp ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)2042-7158 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.ingentaconnect.com/content/rpsgb/jpp ↗ - DOI:
- 10.1093/jpp/rgaa070 ↗
- Languages:
- English
- ISSNs:
- 0022-3573
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5034.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 16578.xml